Search Results - "Mizukami, Takuro"

A randomized phase II study of nutritional and exercise treatment for elderly patients with advanced non-small cell lung or pancreatic cancer: the NEXTAC-TWO study protocol by Miura, Satoru, Naito, Tateaki, Mitsunaga, Shuichi, Omae, Katsuhiro, Mori, Keita, Inano, Toshimi, Yamaguchi, Teiko, Tatematsu, Noriatsu, Okayama, Taro, Morikawa, Ayumu, Mouri, Takako, Tanaka, Hisashi, Kimura, Madoka, Imai, Hisao, Mizukami, Takuro, Imoto, Akira, Kondoh, Chihiro, Shiotsu, Shinsuke, Okuyama, Hiroyuki, Ueno, Makoto, Takahashi, Toshiaki, Tsuji, Tetsuya, Aragane, Hideki, Inui, Akio, Higashiguchi, Takashi, Takayama, Koichi

“…Most advanced elderly cancer patients experience fatigue, anorexia, and declining physical function due to cancer cachexia, for which effective interventions…”
Get full text

An exploration of trifluridine/tipiracil in combination with irinotecan in patients with pretreated advanced gastric cancer by Mizukami, Takuro, Minashi, Keiko, Hara, Hiroki, Nishina, Tomohiro, Amanuma, Yusuke, Takahashi, Naoki, Nakasya, Akio, Takahashi, Masaki, Nakajima, Takako Eguchi

“…Summary Background . Trifluridine/tipiracil (FTD/TPI) and irinotecan are treatment options for heavily pretreated patients with advanced gastric cancer, but…”
Get full text

Decision making for anti-VEGF inhibitor continuation: dip stick? or urine protein/creatinine ratio? (VERSiON UP study) by Nakamura, Michio, Funakoshi, Taro, Kataoka, Shigeki, Horimatsu, Takahiro, Nishikawa, Yoshitaka, Matsubara, Takeshi, Mizukami, Takuro, Goto, Tomoyuki, Tsuchihashi, Kenji, Baba, Eishi, Tsumura, Takehiko, Mihara, Yoshiaki, Hamaguchi, Tetsuya, Yanagita, Motoko, Muto, Manabu

“…Monitoring proteinuria is important for the management of patients with cancer treated with anti-vascular endothelial growth factor (VEGF) or anti-VEGF…”
Get full text

Prospective evaluation and refinement of an S‐1 dosage formula based on renal function for clinical application by Takeuchi, Masashi, Imamura, Chiyo K., Booka, Eisuke, Takeuchi, Hiroya, Mizukami, Takuro, Kawakami, Takeshi, Funakoshi, Taro, Wakuda, Kazushige, Aoki, Yu, Hamamoto, Yasuo, Kitago, Minoru, Kawakubo, Hirofumi, Boku, Narikazu, Tanigawara, Yusuke, Kitagawa, Yuko

“…In patients with impaired renal function, S‐1–related toxicities increase due to higher exposure of 5‐fluorouracil (5‐FU). Our previous pharmacokinetic study…”
Get full text

Clinical utility of geriatric assessment tools in older patients with gastrointestinal cancer by Doi, Ayako, Mizukami, Takuro, Takeda, Hiroyuki, Umemoto, Kumiko, Arai, Hiroyuki, Horie, Yoshiki, Izawa, Naoki, Ogura, Takashi, Sunakawa, Yu

“…Geriatric 8 (G8) and instrumental activities of daily living (IADL) are recommended to predict overall survival (OS) or risk of serious adverse events (SAEs)…”
Get full text

Endoscopic duodenal stent placement versus gastrojejunostomy for unresectable pancreatic cancer patients with duodenal stenosis before introduction of initial chemotherapy (GASPACHO study): a multicenter retrospective study by Azemoto, Nobuaki, Ueno, Makoto, Yanagimoto, Hiroaki, Mizuno, Nobumasa, Kawamoto, Yasuyuki, Maruki, Yuta, Watanabe, Kazuo, Suzuki, Rei, Kaneko, Junichi, Hisada, Yuya, Sato, Hiroki, Kobayashi, Satoshi, Miyata, Hideki, Furukawa, Masayuki, Mizukami, Takuro, Miwa, Haruo, Ohno, Yoshinori, Tsuji, Kunihiro, Tsujimoto, Akiko, Nagano, Hiroaki, Okuyama, Hiroyuki, Asagi, Akinori, Okano, Naohiro, Ishii, Hiroshi, Morizane, Chigusa, Ikeda, Masafumi, Furuse, Junji

“…Abstract Background Endoscopic duodenal stent placement is an alternative technique to gastrojejunostomy for gastric outlet obstruction due to pancreatic…”
Get full text

Analysis of fistula formation of T4 esophageal cancer patients treated by chemoradiotherapy by Taniyama, Tomoko Katsui, Tsuda, Takashi, Miyakawa, Kunihisa, Arai, Hiroyuki, Doi, Ayako, Hirakawa, Mami, Horie, Yoshiki, Mizukami, Takuro, Izawa, Naoki, Ogura, Takashi, Sunakawa, Yu, Nakajima, Takako Eguchi

“…Background and aim Fistula is one of the known complications of T4 esophageal cancer (T4-EC). The standard treatment for T4-EC is chemoradiotherapy, but…”
Get full text

REVIVE study: a prospective observational study in chemotherapy after nivolumab therapy for advanced gastric cancer by Narita, Yukiya, Shoji, Hirokazu, Kawai, Sadayuki, Mizukami, Takuro, Nakamura, Michio, Moriwaki, Toshikazu, Yamanaka, Takeharu, Sunakawa, Yu, Kawakami, Hisato, Nishina, Tomohiro, Misumi, Toshihiro, Muro, Kei

“…Nivolumab is an increasingly used standard care treatment for heavily pretreated patients with advanced gastric cancer, with increasing clinical use in Japan…”
Get full text

Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab based on early tumor shrinkage in RAS wild‐type metastatic colorectal cancer: A phase II trial (HYBRID) by Arai, Hiroyuki, Tsuda, Takashi, Sunakawa, Yu, Shimokawa, Mototsugu, Akiyoshi, Kohei, Tokunaga, Shinya, Shoji, Hirokazu, Kunieda, Kenji, Kotaka, Masahito, Matsumoto, Toshihiko, Nagata, Yusuke, Mizukami, Takuro, Mizuki, Fumitaka, Danenberg, Kathleen D., Boku, Narikazu, Nakajima, Takako Eguchi

“…Background Long‐term anti‐EGFR antibody treatment increases the risk of severe dermatologic toxicities. This single‐arm, phase II trial aimed to investigate…”
Get full text

Clinical Utility of Genomic Profiling Tests in Patients with Advanced Gastrointestinal Cancers by Takeda, Hiroyuki, Imoto, Kiyomi, Umemoto, Kumiko, Doi, Ayako, Arai, Hiroyuki, Horie, Yoshiki, Mizukami, Takuro, Oguri, Tomoyo, Ogura, Takashi, Izawa, Naoki, Yamamoto, Hiroyuki, Yamano, Yoshihisa, Sunakawa, Yu

“…Background Comprehensive analyses of cancer-related genomic alterations are expected to lead to increased availability of targeted therapies. However, in…”
Get full text

Phase I study of the anti-heparin-binding epidermal growth factor-like growth factor antibody U3-1565 with cetuximab in patients with cetuximab- or panitumumab-resistant metastatic colorectal cancer by Nakajima, Takako Eguchi, Boku, Narikazu, Doi, Ayako, Arai, Hiroyuki, Mizukami, Takuro, Horie, Yoshiki, Izawa, Naoki, Hirakawa, Mami, Ogura, Takashi, Tsuda, Takashi, Sunakawa, Yu

“…Summary KRAS wild-type colorectal cancers initially responsive to anti-endothelial growth factor receptor (EGFR) antibodies [cetuximab (Cetu)/panitumumab…”
Get full text

Clinicopathological and genetic differences between low‐grade and high‐grade colorectal mucinous adenocarcinomas by Yoshioka, Yasumasa, Togashi, Yosuke, Chikugo, Takaaki, Kogita, Akihiro, Taguri, Masataka, Terashima, Masato, Mizukami, Takuro, Hayashi, Hidetoshi, Sakai, Kazuko, de Velasco, Marco A., Tomida, Shuta, Fujita, Yoshihiko, Tokoro, Tadao, Ito, Akihiko, Okuno, Kiyotaka, Nishio, Kazuto

“…BACKGROUND Although colorectal mucinous adenocarcinomas (MCs) are conventionally regarded as exhibiting high‐grade differentiation, they can be divided by…”
Get full text

Early morphological change for predicting outcome in metastatic colorectal cancer after regorafenib by Arai, Hiroyuki, Miyakawa, Kunihisa, Denda, Tadamichi, Mizukami, Takuro, Horie, Yoshiki, Izawa, Naoki, Hirakawa, Mami, Ogura, Takashi, Tsuda, Takashi, Sunakawa, Yu, Nakajima, Takako Eguchi

“…It is unclear whether early morphological change (EMC) is a predictive marker for regorafenib in metastatic colorectal cancer (mCRC). Therefore, the present…”
Get full text

Prediction of esophagogastric varices associated with oxaliplatin administration by Satta, Yosuke, Shigefuku, Ryuta, Watanabe, Tsunamasa, Mizukami, Takuro, Tsuda, Takashi, Suzuki, Tatsuya, Ehira, Takuya, Hattori, Nobuhiro, Kiyokawa, Hirofumi, Nakahara, Kazunari, Ikeda, Hiroki, Matsunaga, Kotaro, Takahashi, Hideaki, Matsumoto, Nobuyuki, Okuse, Chiaki, Suzuki, Michihiro, Sunakawa, Yu, Yasuda, Hiroshi, Itoh, Fumio

“…Background Oxaliplatin is a key drug for the chemotherapy of colorectal cancer; however, it is also known to cause non‐cirrhotic portal hypertension. We aimed…”
Get full text

The Nationwide Cancer Genome Screening Project in Japan, SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced colorectal cancer by Kato, Takeshi, Okamoto, Wataru, Hamaguchi, Tetsuya, Hara, Hiroki, Taniguchi, Hiroya, Mizukami, Takuro, Denda, Tadamichi, Moriwaki, Toshikazu, Esaki, Taito, Yuki, Satoshi, Oki, Eiji, Kajiwara, Takeshi, Kudo, Toshihiro, Naruge, Daisuke, Tamura, Takao, Fujii, Satoshi, Doi, Toshihiko, Ohtsu, Atsushi, Shitara, Kohei, Yoshino, Takayuki

“…Abstract only…”
Get full text

Development of an S-1 dosage formula based on renal function by a prospective pharmacokinetic study by Booka, Eisuke, Imamura, Chiyo K., Takeuchi, Hiroya, Hamamoto, Yasuo, Gomi, Daisuke, Mizukami, Takuro, Ichiyama, Takashi, Tateishi, Kazunari, Takahashi, Tsunehiro, Kawakubo, Hirofumi, Soejima, Kenzo, Boku, Narikazu, Tanigawara, Yusuke, Kitagawa, Yuko

“…Background S-1 is an oral anticancer drug, containing tegafur (a prodrug of 5-fluorouracil, 5-FU), 5-chloro-2,4-dihydroxypyridine, and potassium oxonate. As…”
Get full text

Chemotherapy in cancer patients undergoing haemodialysis: a nationwide study in Japan by Funakoshi, Taro, Horimatsu, Takahiro, Nakamura, Michio, Shiroshita, Koichi, Suyama, Koichi, Mukoyama, Masashi, Mizukami, Takuro, Sakurada, Tsutomu, Baba, Eishi, Tsuruya, Kazuhiko, Nozaki, Akira, Yahata, Kensei, Ozaki, Yukinori, Ubara, Yoshifumi, Yasui, Hisateru, Yoshimoto, Akihiro, Fukuma, Shingo, Kondo, Naoya, Matsubara, Takeshi, Matsubara, Kazuo, Fukuhara, Shunichi, Yanagita, Motoko, Muto, Manabu

“…BackgroundCancer is a major cause of death in patients undergoing haemodialysis. However, information about the actual clinical practice of chemotherapy for…”
Get full text

Esophagogastric varices were diagnosed in a non-cirrhotic liver case during long-term follow-up after oxaliplatin-based chemotherapy by Shigefuku, Ryuta, Watanabe, Tsunamasa, Mizukami, Takuro, Matsunaga, Kotaro, Hattori, Nobuhiro, Ehira, Takuya, Suzuki, Tatsuya, Nakano, Hiroyasu, Sato, Yoshinori, Matsuo, Yasumasa, Nakahara, Kazunari, Ikeda, Hiroki, Matsumoto, Nobuyuki, Tsuda, Takashi, Katayama, Masafumi, Koizumi, Satoshi, Okuse, Chiaki, Suzuki, Michihiro, Otsubo, Takehito, Nakajima, Takako Eguchi, Yasuda, Hiroshi, Itoh, Fumio

“…Oxaliplatin, a chemotherapeutic agent for colorectal cancer, has been associated with pathological evidence of sinusoidal endothelial injury in the liver…”
Get full text

Role of nutritional care and general guidance for patients with advanced or metastatic gastric cancer by Mizukami, Takuro, Piao, Yongzhe

“…Patients with advanced or metastatic gastric cancer often suffer from malnutrition, which can have an impact on quality of life, increase the toxicity of…”
Get full text

Targeting EGFR and RAS/RAF Signaling in the Treatment of Metastatic Colorectal Cancer: From Current Treatment Strategies to Future Perspectives by Mizukami, Takuro, Izawa, Naoki, Nakajima, Takako Eguchi, Sunakawa, Yu

“…The epidermal growth factor receptor (EGFR) and RAS/RAF signaling pathway plays pivotal roles in tumor progression via proliferation, survival, invasion, and…”
Get full text